GCM
ANAB icon

Gladius Capital Management’s AnaptysBio ANAB Stock Holding History

Gladius Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,481
Closed -$26.6K – 320
2023
Q3 		$26.6K Buy
1,481
+399
+37% +$7.61K ﹤0.01% 320
2023
Q2 		$22K Buy
+1,082
New +$21.9K ﹤0.01% 297
2022
Q3 		– Sell
-892
Closed -$19K – 371
2022
Q2 		$19K Buy
+892
New +$19.8K ﹤0.01% 319

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Gladius Capital Management's ANAB Position: Q4 2023 in Review

Gladius Capital Management sold out of AnaptysBio (ANAB) in Q4 2023, closing a stake of 1,481 shares — an estimated $26.6K sold.

Gladius Capital Management first reported a position in ANAB in Q2 2022 and held it in 3 quarters. The position peaked at $26.6K in Q3 2023. 119 funds tracked by Wall St. Rank hold ANAB as of Q4 2023.

  • Gladius Capital Management reported no remaining AnaptysBio position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 1,481 AnaptysBio shares in Q4 2023, an estimated $26.6K.
  • Gladius Capital Management first reported a position in AnaptysBio in Q2 2022 and held it in 3 quarters.
  • Gladius Capital Management's AnaptysBio position peaked at $26.6K in Q3 2023.
  • 119 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.